 |
|
|
|
April 2001 Cover
|
|
Preliminary data from a phase I/II trial of azodicarbonamide (ADA) indicates that the HIV-1 zinc finger inhibitor is generally safe and could be beneficial to some AIDS patients who are experiencing virologic failure, when used in combination with standard
antiviral therapies. Researchers from the Ludwig- Maximilians-Universitat in Germany report that most of the 15 subjects tolerated ADA well and that toxicity was dependent upon dosage. The tests indicated that ADA increased the percentage of CD4 cells and the
CD4/CD8 ratio and decreased plasma RNA viral load levels in comparison to baseline data.
Editor's Note: from Reuters Health Info Services
You are not logged in.
No comments yet, but
click here to be the first to comment on this
HIV Digest!
|
|
|
|
|
